ArticleBiochemistry and biophysics reports2025
Ccar1 prevents β-catenin nuclear translocation to sustain ground-state pluripotency in mouse ESCs under R2i.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual inhibition of extracellular signal-regulated kinase (MEK) and transforming growth factor beta (TGFβ), known as R2i, sustains ground-state pluripotency in mouse embryonic stem cells (mESCs). To understand the molecular mechanisms of R2i, we analyzed the proteomic profile of mESCs cultured under R2i conditions in our previous study. Our data showed overexpression of the cell cycle and apoptosis regulator 1 (Ccar1) under R2i conditions. In this study, we investigated the role of Ccar1 in the pluripotency of mESCs through the loss-of-function approach. We hypothesize that Ccar1 contributes to the maintenance of pluripotency by interacting with β-catenin and preventing its translocation to the nucleus. Therefore, we used siRNA against Ccar1 and then analyzed the localization of β-catenin and the expression of its target genes by immunofluorescence assay and qRT-PCR. Immunofluorescence analysis demonstrated that siRNA-mediated downregulation of Ccar1 promoted the nuclear translocation of β-catenin. qRT-PCR analysis showed a significant reduction of pluripotency marker genes as well as some cell cycle markers such as
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.